AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, respectively. Kim and his team will focus on the development of the company’s late-stage immuno-oncology combinations programme, aiming to develop combination regimens that will deliver innovative medicines to patients.
{iframe}https://www.pmlive.com/pharma_appointments/az_and_medimmune_bolsters_immuno-oncology_leadership_1200557{/iframe}